Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Research & Development (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Research & Development for 4 consecutive years, with $41.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 22.59% to $41.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $178.6 million, a 49.99% increase, with the full-year FY2024 number at $150.2 million, up 20.77% from a year prior.
  • Research & Development was $41.6 million for Q3 2025 at Centessa Pharmaceuticals, down from $42.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $60.9 million in Q4 2024 to a low of $22.7 million in Q1 2024.
  • A 4-year average of $36.5 million and a median of $33.7 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 37.24% in 2023, then soared 104.85% in 2024.
  • Centessa Pharmaceuticals' Research & Development stood at $27.8 million in 2022, then rose by 6.76% to $29.7 million in 2023, then soared by 104.85% to $60.9 million in 2024, then plummeted by 31.72% to $41.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Research & Development are $41.6 million (Q3 2025), $42.7 million (Q2 2025), and $33.4 million (Q1 2025).